The Effect of Local Allergic Reaction to Intralesional Glucantime on Recovery Course of Cutaneous Leishmaniasis

Document Type : Original Article (s)

Authors

1 Resident, Department of Dermatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Associate Professor, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 General Practitioner, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Systemic or intralesional injection of Glucantime in treatment of cutaneous leishmaniasis, sometimes leads to a local allergic reaction. This study aimed to evaluate the effect of local allergic reaction to intralesional Glucantime on recovery course of cutaneous leishmaniasis.Methods: In a retrospective cross-sectional study, the data of patient records of cases with cutaneous leishmaniasis, who underwent local treatment with Glucantime in Imam Reza dermatology clinic, Mashhad, Iran, from March 2006 to March 2011, were evaluated. All cases that showed a localized allergic reaction to Glucantime were selected as the case group and the cases of cutaneous leishmaniasis without any allergic reaction to treatment were selected as control group. Patients were evaluated in subsequent follow-up periods for improvement after Glucantime injection.Findings: The mean number of injections needed for complete recovery was 6.54± 3.76 in patients with topical allergic reaction and 9.77 ± 5.14 in control group; there was a statistically significant difference between two groups (P = 0.002). The time to complete recovery in patients with topical allergic reaction to Glucantime was insignificantly shorter.Conclusion: This study showed that patients with local allergic reaction to Glucantime require fewer numbers of injections to achieve complete recovery than non-allergic patients.

Keywords

References

  1. Brasileiro A, Martin-Ezquerra G, Garcia-Martinez P, Pujol RM, Gimenez-Arnau AM. Allergic reactions to meglumine antimoniate while treating cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2017; 31(1): e59-e60.
  2. Cordoba S, Gandolfo CM, Aguado M, Huerta-Brogera M, Romero A, Martinez-Moran C, et al. Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. Allergy 2012; 67(12): 1609-11.
  3. Calvopina M, Cevallos W, Paredes Y, Puebla E, Flores J, Loor R, et al. Intralesional infiltration with meglumine antimoniate for the treatment of leishmaniasis recidiva cutis in Ecuador. Am J Trop Med Hyg 2017; 97(5): 1508-12.
  4. Choi JW, Cho S, Lee JH. Does immunotherapy of viral warts provide beneficial effects when it is combined with conventional therapy? Ann Dermatol 2011; 23(3): 282-7.
  5. Al-Mutairi N, Al-Doukhi A, Al-Farag S, Al-Haddad A. Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatr Dermatol 2010; 27(4): 388-94.
  6. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 2009; 64(12): 1699-714.
  7. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91(4): 1390-5.
  8. Da-Cruz AM, De Oliveira MP, De Luca PM, Mendonca SC, Coutinho SG. Tumor necrosis factor-α in human American tegumentary leishmaniasis. Mem Ins. Oswaldo Cruz 1996; 91(2): 225-9.
  9. Carvalho LP, Passos S, Schriefer A, Carvalho EM. Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol 2012; 3: 301.
Journal of Isfahan Medical School
Volume 38, Issue 563 - Serial Number 563
January and February 2020
Pages 62-66

Files

History

  • Receive Date: 04 February 2020
  • Revise Date: 07 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics